HRP20192345T1 - Medicinski tretmani na bazi anamorelina - Google Patents
Medicinski tretmani na bazi anamorelina Download PDFInfo
- Publication number
- HRP20192345T1 HRP20192345T1 HRP20192345TT HRP20192345T HRP20192345T1 HR P20192345 T1 HRP20192345 T1 HR P20192345T1 HR P20192345T T HRP20192345T T HR P20192345TT HR P20192345 T HRP20192345 T HR P20192345T HR P20192345 T1 HRP20192345 T1 HR P20192345T1
- Authority
- HR
- Croatia
- Prior art keywords
- anamorelin
- use according
- patient
- cachexia
- procedure
- Prior art date
Links
- VQPFSIRUEPQQPP-MXBOTTGLSA-N anamorelin Chemical compound C([C@@]1(C(=O)N(C)N(C)C)CN(CCC1)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 VQPFSIRUEPQQPP-MXBOTTGLSA-N 0.000 title claims 21
- 229950005896 anamorelin Drugs 0.000 title claims 21
- 108010052640 anamorelin Proteins 0.000 title claims 21
- 238000011282 treatment Methods 0.000 title claims 2
- 206010006895 Cachexia Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 3
- VFYAEUWJFGTGGO-GHTUPXNNSA-N 2-amino-n-[(2r)-1-[(3r)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide;hydrochloride Chemical compound Cl.C([C@@]1(C(=O)N(C)N(C)C)CN(CCC1)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 VFYAEUWJFGTGGO-GHTUPXNNSA-N 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 206010016256 fatigue Diseases 0.000 claims 2
- 229940127240 opiate Drugs 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 231100000226 haematotoxicity Toxicity 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (15)
1. Anamorelin za uporabu u postupku za tretman zamora koji nastaje uslijed tumorske kaheksije kod ljudskog pacijenta s rakom, pri čemu je navedena kaheksija definirana kao indeks tjelesne mase manji od 20 Kg/m2, pri čemu postupak sadrži svakodnevnu primjenu anamorelina kod navedenog pacijenta tijekom terapeutski efikasnog vremenskog perioda.
2. Anamorelin za uporabu u postupku za poboljšanje kvalitete života, mjereno pomoću FAACT u domeni anoreksije/kaheksije, kod ljudskog pacijenta s rakom, pri čemu je navedena kaheksija definirana kao indeks tjelesne mase manji od 20 Kg/m2, naznačen time što postupak sadrži svakodnevnu primjenu anamorelina kod navedenog pacijenta tokom terapeutski efikasnog vremenskog perioda.
3. Anamorelin za uporabu u postupku za povećanje ukupne tjelesne mase, čiste tjelesne mase, mase masnog tkiva kod ljudskog pacijenta koji pati od tumorske kaheksije, pri čemu je navedena kaheksija definirana kao indeks tjelesne mase manji od 20 kg/m2, pri čemu postupak sadrži svakodnevnu primjenu anamorelina kod navedenog pacijenta tijekom terapeutski efikasnog vremenskog perioda.
4. Anamorelin za uporabu prema patentnom zahtjevu 1 naznačen time što je navedeni zamor izazvan depresijom, anemijom, sarkopenijom, anoreksijom, neuhranjenošću u vezi s povraćanjem, hemotoksičnošću, upotrebom opijata, i/ili poremećajima spavanja.
5. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što ljudski pacijent pati od neoperabilnog nesitnoćelijskog raka pluća, stadijuma III ili IV.
6. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni anamorelin predstavlja anamorelin HCl u količini od 100 mg, na osnovu težine soli.
7. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni anamorelin predstavlja anamorelin HCl u količini od 100 mg, na osnovu težine soli, primijenjen oralno jednom dnevno, najmanje jedan sat prije prvog obroka.
8. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni efikasan vremenski period iznosi dvanaest tjedana.
9. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni efikasan vremenski period iznosi od 13 do 24 tjedna.
10. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni pacijent ima funkcionalni status na ECOG od 2 ili više.
11. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni pacijent ima skvamoznu histologiju tumora.
12. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što je navedeni rak metastazirao.
13. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni pacijent ne prima hemioterapiju ili radioterapiju.
14. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni pacijent prima hemioterapiju ili radioterapiju.
15. Anamorelin za uporabu prema bilo kojem od patentnih zahtjeva 1-3 naznačen time što navedeni pacijent prima opijate i/ili antiemetike.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045976P | 2014-09-04 | 2014-09-04 | |
| EP15838548.4A EP3188599B1 (en) | 2014-09-04 | 2015-08-28 | Medical treatments based on anamorelin |
| PCT/US2015/047435 WO2016036598A1 (en) | 2014-09-04 | 2015-08-28 | Medical treatments based on anamorelin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192345T1 true HRP20192345T1 (hr) | 2020-03-20 |
Family
ID=55436476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192345TT HRP20192345T1 (hr) | 2014-09-04 | 2019-12-30 | Medicinski tretmani na bazi anamorelina |
Country Status (44)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159609A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Peanut formulations and uses thereof |
| US9675600B2 (en) | 2014-09-04 | 2017-06-13 | Helsinn Healthcare Sa | Medical treatments based on anamorelin |
| US11229673B2 (en) | 2019-05-10 | 2022-01-25 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
| WO2021038519A1 (en) | 2019-08-30 | 2021-03-04 | Helsinn Healthcare Sa | Methods of manufacturing anamorelin tablets having improved stability |
| JPWO2021079978A1 (hr) * | 2019-10-24 | 2021-04-29 | ||
| TW202327596A (zh) * | 2021-09-17 | 2023-07-16 | 瑞士商赫爾辛保健公司 | 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| ECSP993020A (es) | 1999-06-16 | 1999-08-12 | Terapia de combinacion para la fragilidad musculoesqueletica | |
| ECSP993021A (es) | 1999-06-16 | 1999-08-12 | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| US20010020012A1 (en) | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| CN1863550A (zh) * | 2003-08-06 | 2006-11-15 | 加斯特罗泰克药物公司 | 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用 |
| JP2007523048A (ja) * | 2003-08-06 | 2007-08-16 | ガストロテック・ファルマ・アクティーゼルスカブ | 分泌促進物質の使用 |
| WO2005097261A1 (en) | 2004-03-30 | 2005-10-20 | Sapphire Therapeutics, Inc. | Method of reducing c-reactive protein using growth hormone secretagogues |
| KR101324340B1 (ko) * | 2004-06-29 | 2013-10-31 | 헬신 세라퓨틱스 (유.에스.) 인크. | (3ｒ)-1-(2-메틸알라닐-ｄ-트립토필)-3-(페닐메틸)-3-피페리딘카르복실산 1,2,2-트리메틸하이드라지드의 결정 형태 |
| JP2010518158A (ja) * | 2007-02-13 | 2010-05-27 | ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド | 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法 |
| TWI429436B (zh) | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| JO3353B1 (ar) * | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| EP2854810A4 (en) | 2012-05-25 | 2016-04-06 | Raqualia Pharma Inc | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA |
| US9675600B2 (en) | 2014-09-04 | 2017-06-13 | Helsinn Healthcare Sa | Medical treatments based on anamorelin |
-
2015
- 2015-08-28 US US14/839,038 patent/US9675600B2/en active Active
- 2015-08-28 KR KR1020177008748A patent/KR101881264B1/ko active IP Right Grant
- 2015-08-28 UA UAA201702308A patent/UA120765C2/uk unknown
- 2015-08-28 JP JP2017512679A patent/JP6356907B2/ja active Active
- 2015-08-28 RS RS20191688A patent/RS59751B1/sr unknown
- 2015-08-28 BR BR112017003552A patent/BR112017003552A2/pt not_active Application Discontinuation
- 2015-08-28 LT LT15838548T patent/LT3188599T/lt unknown
- 2015-08-28 EP EP15838548.4A patent/EP3188599B1/en active Active
- 2015-08-28 AU AU2015312231A patent/AU2015312231B2/en active Active
- 2015-08-28 CN CN201710646685.0A patent/CN107375285A/zh active Pending
- 2015-08-28 WO PCT/US2015/047435 patent/WO2016036598A1/en active Application Filing
- 2015-08-28 CR CR20170121A patent/CR20170121A/es unknown
- 2015-08-28 CN CN201580059744.3A patent/CN107205389A/zh active Pending
- 2015-08-28 KR KR1020217008765A patent/KR102307275B1/ko active IP Right Grant
- 2015-08-28 MA MA40607A patent/MA40607B1/fr unknown
- 2015-08-28 PE PE2017000359A patent/PE20171109A1/es unknown
- 2015-08-28 KR KR1020187020062A patent/KR102234319B1/ko active IP Right Grant
- 2015-08-28 PL PL15838548T patent/PL3188599T3/pl unknown
- 2015-08-28 HU HUE15838548A patent/HUE046894T2/hu unknown
- 2015-08-28 EA EA201790352A patent/EA035578B1/ru unknown
- 2015-08-28 EP EP19183144.5A patent/EP3590338A3/en not_active Withdrawn
- 2015-08-28 ES ES15838548T patent/ES2761777T3/es active Active
- 2015-08-28 GE GEAP201514459A patent/GEP20186939B/en unknown
- 2015-08-28 MD MDA20170025A patent/MD4710C1/ro active IP Right Grant
- 2015-08-28 CN CN202111026050.3A patent/CN113577073A/zh active Pending
- 2015-08-28 CN CN202111027023.8A patent/CN113577074A/zh active Pending
- 2015-08-28 TN TN2017000040A patent/TN2017000040A1/en unknown
- 2015-08-28 SI SI201530994T patent/SI3188599T1/sl unknown
- 2015-08-28 MY MYPI2017700714A patent/MY187167A/en unknown
- 2015-08-28 DK DK15838548T patent/DK3188599T3/da active
- 2015-08-28 AP AP2017009772A patent/AP2017009772A0/en unknown
- 2015-08-28 PT PT158385484T patent/PT3188599T/pt unknown
- 2015-08-28 CN CN201811119404.7A patent/CN109172575A/zh active Pending
- 2015-08-28 CA CA2959158A patent/CA2959158A1/en active Pending
- 2015-08-28 ME MEP-2019-372A patent/ME03597B/me unknown
- 2015-08-28 MX MX2017002825A patent/MX361741B/es active IP Right Grant
- 2015-08-28 SG SG11201701567UA patent/SG11201701567UA/en unknown
- 2015-08-30 JO JOP/2015/0210A patent/JO3541B1/ar active
- 2015-09-01 TW TW104128838A patent/TWI639429B/zh active
- 2015-09-02 UY UY0001036286A patent/UY36286A/es not_active Application Discontinuation
- 2015-09-03 AR ARP150102818A patent/AR103118A1/es unknown
-
2017
- 2017-02-20 IL IL250692A patent/IL250692B/en active IP Right Grant
- 2017-03-02 CL CL2017000494A patent/CL2017000494A1/es unknown
- 2017-03-02 PH PH12017500392A patent/PH12017500392A1/en unknown
- 2017-03-03 NI NI201700024A patent/NI201700024A/es unknown
- 2017-03-03 SV SV2017005400A patent/SV2017005400A/es unknown
- 2017-03-03 DO DO2017000055A patent/DOP2017000055A/es unknown
- 2017-03-30 EC ECIEPI201719893A patent/ECSP17019893A/es unknown
- 2017-04-03 CO CONC2017/0003263A patent/CO2017003263A2/es unknown
- 2017-05-09 US US15/590,025 patent/US10278964B2/en active Active
-
2018
- 2018-06-14 JP JP2018113592A patent/JP6923486B2/ja active Active
-
2019
- 2019-02-14 US US16/275,669 patent/US10894041B2/en active Active
- 2019-12-16 CY CY20191101321T patent/CY1122746T1/el unknown
- 2019-12-30 HR HRP20192345TT patent/HRP20192345T1/hr unknown
-
2020
- 2020-12-11 US US17/119,482 patent/US11723902B2/en active Active
-
2021
- 2021-02-26 JP JP2021029775A patent/JP7044918B2/ja active Active
-
2023
- 2023-06-22 US US18/212,720 patent/US20240024303A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192345T1 (hr) | Medicinski tretmani na bazi anamorelina | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| UY37773A (es) | Imidazopirimidinas diazabicíclicas sustituidas y su uso | |
| CL2019000129A1 (es) | Compuestos diazaheterobicíclicos sustituidos y su uso. | |
| PH12018501903A1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| EA201290883A1 (ru) | Способы диагностики и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака | |
| WO2012106548A3 (en) | Devices, systems and methods for the targeted treatment of movement disorders | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| EA201491605A1 (ru) | Способы улучшения функции диафрагмы | |
| EA201491334A1 (ru) | Композиции и способы для лечения метаболических расстройств | |
| EA201591290A3 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| MX2024002360A (es) | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. | |
| BR112016016880A2 (pt) | Combinação para tratar câncer e seu uso, kit, e composição farmacêutica | |
| MX2018007152A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. | |
| JP2017526695A5 (hr) | ||
| WO2017011356A3 (en) | Mcj inhibitors for use in treating drug-induced diseases and conditions | |
| WO2013052158A3 (en) | Targeted nanovectors and their use for treatment of brain tumors | |
| EA201591693A1 (ru) | Новые соединения, модулирующие контроль над дыханием, и способы их применения | |
| CN204364185U (zh) | 一种矫正器 | |
| Gui et al. | C29 MUSCLES, EXERCISE ASSESSMENT, AND REHABILITATION: Effect Of Exercise Training On Cancer Cachexia In Lewis Lung Carcinoma (llc) Mouse Model | |
| RU2014150506A (ru) | Велипариб в комбинации с лучевой терапией всего мозга для лечения метастазов в головной мозг | |
| Cazzato et al. | Off-line rTMS of left Dorsolateral Prefrontal Cortex reduces food cravings in females but not males | |
| Wei | Harnessing autophagy to potentiate the antitumor effects of the tyrosine kinase inhibitor cabozantinib in prostate cancer cells | |
| UA116484U (uk) | Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом | |
| UA82436U (ru) | Способ реабилитации детей с экстрасистолической аритмией |